The analysis of multicomponent pharmaceutical formulations containing drugs with significant diverse physicochemical properties, like 6 orders of magnitude of pKa values, which permanently represents a significant challenge in modern pharmaceutical analysis. The simultaneous determination of multiple active agents offers substantial advantages by reducing analysis time and resource consumption. Furthermore, the increased analytical demand during health emergencies highlights the necessity for validated, rapid, and reliable methods capable of supporting both therapeutic assessment and regulatory decision-making. In the present study, a reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed and optimized for the simultaneous determination of four analytes: clotrimazole, miconazole, metronidazole, and lidocaine. Various approaches were investigated for mobile phase composition and column selection to achieve optimal separation and accurate quantitative determination. Chromatographic separation was examined using several columns, including Waters Spherisorb CN (250 × 4.6 mm, 5 µm), LiChrospher 100 CN (125 × 4 mm, 5 µm), LiChrospher 100 CN (250 × 4 mm, 5 µm), Zorbax SB CN (150 × 4.6 mm, 3.5 µm and 250 × 4.6 mm, 5 µm), Zorbax Rx C8 (250 × 4.6 mm, 5 µm), and Zorbax SB Phenyl (150 × 4.6 mm, 3.5 µm). Isocratic elution was employed using mixtures of acetonitrile, methanol, and phosphoric acid or trifluoroacetic acid in different proportions at flow rates of 1.0 and 1.2 mL min− 1. UV-detection was carried out at 215 nm. The developed method demonstrated excellent system suitability and complied with ICH Q2 (R2) validation requirements, showing satisfactory linearity (R2 > 0.999), accuracy (recoveries within 98–102%), and precision (RSD < 2%). In addition, the sustainability of the proposed method was comprehensively assessed using AGREE, MoGAPI, and BAGI tools to evaluate its greenness, whiteness, blueness and applicability. Overall, the method provides a robust, efficient, and sustainable analytical platform for quality control laboratories, enabling reliable routine analysis of multicomponent pharmaceutical products and therapeutic surveillance.
Zhuravel et al. (Thu,) studied this question.